CytoSorbents(CTSO) - 2022 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for Q4 2022 were approximately $9.4 million, a 13% decrease compared to Q4 2021's $10.8 million [28] - Product sales in Q4 2022 were $7.6 million, a 21% decline from $9.7 million in Q4 2021 [28] - Grant revenue for Q4 was $1.7 million compared to $1.1 million in the prior year, with gross profit margins on product sales at 75% for Q4 2022, down from 78% the previous year [8][28] - Total revenue for 2022 was $34.7 million, a 21% decrease from $43.2 million in 2021, with product sales declining by 27% [99] Business Line Data and Key Metrics Changes - COVID-19 product sales were negligible in Q4 2022, down from $1.7 million in Q4 2021 [29] - Core non-COVID-19 product sales were 30% higher than in 2019, indicating recovery in the core business [30] - The company expects gross margins to improve to 75% to 80% as production ramps up in the new facility [9][108] Market Data and Key Metrics Changes - Sales in Germany, the largest market, were $3.3 million in Q4 2022, a 33% increase over Q3 2022 [98] - The company noted a 27% decline in business due to pandemic-related challenges but reported a 31% increase compared to the last pre-pandemic year [17] Company Strategy and Development Direction - The company is focusing resources on the STAR-T trial, which is expected to support FDA marketing approval for DrugSorb-ATR [31][21] - The STAR-T trial has seen accelerated enrollment, with over 200 patients enrolled and initial data readouts expected in 2023 [13][37] - The company aims to address new customer groups and enter mainstream markets, particularly in cardiovascular therapy [123] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in international sales growth, particularly in Europe, and noted ongoing initiatives to drive sales growth [25] - The company acknowledged challenges in the healthcare market due to staffing shortages and inflation but indicated a stabilization in Q4 2022 and continued growth into 2023 [43][122] - Management highlighted the importance of new clinical data and guidelines as catalysts for commercial adoption of their products [65][124] Other Important Information - The company reduced overall headcount by 10% in 2022 and shifted R&D employees to grant-funded programs to manage cash burn [10] - The company has a grant backlog of $11.5 million, typically spread over multiple years [76] Q&A Session Summary Question: What is the outlook for 2023 regarding revenue reduction due to COVID-19? - Management indicated that headwinds from COVID-19 have lessened, and they expect improved conditions in 2023 [84] Question: Can a prospective study for endocarditis support U.S. approval? - Management confirmed the possibility of a prospective study for endocarditis but emphasized the focus on current trials [86] Question: What is the status of gross margin recovery? - Management noted that gross margins are expected to improve due to efficiencies from the new facility and increased demand [66]